A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD:the EXTEND Study

References

• Anon. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899–913
   Web of Science ®Google Scholar
• The Canadian Study of Health and Aging Working Group. The incidence of dementia in Canada. Neurology 2000;55:66–73
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021–31
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–45
   PubMed Web of Science ®Google Scholar
• Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 1999;318:633–40
   Google Scholar
• Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1: 55–65
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month, randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261–8
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E, et al. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicentre randomised controlled trial. Br Med J 2000;32:1–7
   Google Scholar
• Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481–48
   PubMed Web of Science ®Google Scholar
• Rosler M, Retz W, Retz-Junginger P, et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1998;11:211–6
   Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer’s disease. Neurology 2001;57:613–20
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273–7
   PubMed Web of Science ®Google Scholar
• Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999;12:307–23
   Web of Science ®Google Scholar
• Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer’s disease? Drugs Aging 2001;18:891–8
   PubMed Web of Science ®Google Scholar
• Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001;17:159–65
   PubMed Web of Science ®Google Scholar
• Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131–8
   PubMed Web of Science ®Google Scholar
• Patterson CJ, Gauthier S, Bergman H, et al. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999;160(Suppl 12):S1–S15
   Web of Science ®Google Scholar
• Inglis F. Switching acetylcholinesterase inhibitor therapy in AD. Prog Neurol Psychiatry 2001;5:24–5
   Google Scholar
• Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129–38
   Google Scholar
• Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer’s disease – donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288–9
   PubMed Web of Science ®Google Scholar
• Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812
   PubMed Web of Science ®Google Scholar
• Clinical global impressions (CGI). In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976. p. 218–22
   Google Scholar
• Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980;20:649–55
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Lorentz WJ, Scanlan JM, Borson S. Brief screening tests for dementia. Can J Psychiatry 2002;47:723–33
   Google Scholar
• Tekin S, Fairbanks LA, O’Connor S. Activities of daily living in Alzheimer’s disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry 2001;9:81–6
   Google Scholar
• Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21:1317–27
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Hansen LA, Alford M, et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease. Neurology 2000;55:1278–83
   PubMed Web of Science ®Google Scholar
• Ho GJ, Hansen LA, Alford MF, et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. Neuroreport 2002;13:1825–8
   PubMed Web of Science ®Google Scholar
• Jacobs D, Sano M, Marder K, et al. Age at onset of Alzheimer’s disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994;44:1215–20
   PubMed Web of Science ®Google Scholar
• Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–75
   Google Scholar
• Rosser MN, Iverson LL, Reynolds GP, et al. Neurochemical characteristics of early and late onset types of Alzheimer’s disease. Br Med J (Clin Res Ed) 1984;288:961–4
   PubMed Web of Science ®Google Scholar
• Schoenmaker N, Van Gool WA. The age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol 2004;3:627–30
   PubMed Web of Science ®Google Scholar
• Gauthier S, Keren R, Juby A, Morelli L. EXTEND Program: Interim data analysis suggests that rivastigmine benefits patients with AD who have failed on a cholinesterase inhibitor. J Can Geriatr Soc 2003;6:132
   Google Scholar
• Gauthier S, Keren R, Juby A, et al. EXTEND: rivastigmine enhances normal daily living in de-novo and switched Alzheimer’s disease treated patients. J Can Geriatr Soc 2004;7:72
   Google Scholar